Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

NCT04794699 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

169

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: IDE397
DRUG: Sacituzumab govitecan

Sponsor

IDEAYA Biosciences